Cecilia Nisticò - Concepedia

Author

Cecilia Nisticò

Also Known As

C Nistico, C Nisticò, C Nistico’, C Nisticò, C. Nistico, C. Nistico', C. Nisticò, C. Nisticò, C. Nisticó, Cecila Nisticò

144

Publications

2.5K

Citations

H-Index

Concepts

All Affiliations

National Cancer Institute Sapienza University of Rome Instituto Nazionale Tumori Regina Elena Istituti di Ricovero e Cura a Carattere Scientifico Candiolo Cancer Institute

About

Cecilia Nisticò is an author at National Cancer Institute specializing in oncology, medicine, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	16	686
2	Pharmacology	11	11	356
3	Immunology	1	1	20
4	Obstetrics	1	1	17
5	Pathology	1	1	55

Cecilia Nisticò

Publications

1.7K

Citations

H-Index

Page 1

	Year	Citations
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial Lucia Del Mastro, Sabino De Placido, Paolo Bruzzi, The Lancet Breast OncologyMedicineDose-dense ChemotherapyBreast CancerCancer Treatment	2015	196
Benefit of taxanes as adjuvant chemotherapy for early breast cancer Emilio Bria, Cecilia Nisticò, Federica Cuppone, Cancer	2006	147
A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study Flavia Novelli, Michele Stanislaw Milella, Elisa Melucci, Breast Cancer Research	2008	104
HER2 Protein and Gene Variation between Primary and Metastatic Breast Cancer: Significance and Impact on Patient Care Alessandra Fabi, Anna Di Benedetto, Giulio Metro, Clinical Cancer Research	2011	98
Impact of Five Prophylactic Filgrastim Schedules on Hematologic Toxicity in Early Breast Cancer Patients Treated With Epirubicin and Cyclophosphamide Paola Papaldo, Massimo Lopez, Paolo Marolla, Journal of Clinical Oncology	2005	96
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial Sabino De Placido, Ciro Gallo, Michelino De Laurentiis, The Lancet Oncology Endocrine OncologyBreast OncologyMedicinePharmacologyEndocrine-sensitive Breast Cancer	2018	86
Addition of Either Lonidamine or Granulocyte Colony-Stimulating Factor Does Not Improve Survival in Early Breast Cancer Patients Treated With High-Dose Epirubicin and Cyclophosphamide Paola Papaldo, Massimo Lopez, Enrico Cortesi, Journal of Clinical Oncology	2003	74
Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials Valentina Rossi, Paola Berchialla, Diana Giannarelli, Cancers	2019	67
Vinorelbine neurotoxicity: clinical and neurophysiological findings in 23 patients. Andrea Pace, Loredana Bove, Cecilia Nisticò, Journal of Neurology Neurosurgery & Psychiatry	1996	56
T-DM1 and brain metastases: Clinical outcome in HER2-positive metastatic breast cancer Alessandra Fabi, Daniele Alesini, Enrichetta Valle, The Breast Neuro-oncologyBreast OncologyBrain MetastasesMedicinePathology	2018	55

Page 1